COVID-19 and beyond: Advantages of the BD Nexiva™ Closed IV Catheter System

Using BD Nexiva™ Catheters to improve safety and reduce cost

The COVID-19 pandemic has heightened clinicians’ awareness of the potential risks of exposure to bloodborne pathogens when starting and managing peripheral IV catheters (PIVCs). COVID-19 has also dramatically increased personal protective equipment (PPE) usage, further impacting the cost burden to facilities and patients. Using the right IV catheter can improve safety and reduce cost.

Using BD Nexiva™ Catheters to improve safety and reduce cost

The threat of COVID-19 is real. The procedural and economic impact on hospitals and healthcare organizations will be felt for years to come. Something as simple as the PIVC you use may address some of the challenges you face. BD Nexiva™ Closed IV Catheter System with demonstrated longer dwell times can reduce complications,1,4 reduce the need for restarts, and potentially minimize exposure to sick patients and unnecessary use of PPE. And it all drops directly to your bottom line. Does your IV catheter do all that?

Longer dwell times

6 days
The BD Nexiva™ IV Closed IV Catheter System has been demonstrated in a clinical study to last up to 6 days.1‡

Reduced PIVC complications can lead to a longer dwell time and minimize the need for painful restarts.1,‡

The BD Nexiva™ Closed IV Catheter System is the only all-in-one PIVC shown to preserve sites for longer.1,‡

Reduced blood exposure

98%
The BD Nexiva™ Pre-assembled Catheter System has been shown to significantly reduce blood exposure during insertion by 98%.1,‡

BD blood control technologies provide protection from blood exposure for clinicians and deliver a cost savings related to cleanup supplies.2 †

In a 2010 clinical study, the cost of using BD Nexiva™ IV Catheters with a customized securement dressing was 75% of the cost of a traditional catheter with a stabilization device and extension set.7

The BD Nexiva™ Pre-assembled Catheter System has been demonstrated to significantly reduce blood exposure during insertion by 98%.1,‡

Reduced complications

84%
The BD Nexiva™ Closed IV Catheter System with integrated extension tubing and stabilization platform reduces the risk of dislodgement by 84% and related complications.1,‡

In a 2014 clinical study, results demonstrated a significant reduction in the rate of phlebitis (grade 2 or higher) (36%), catheter-related complications (25%), and infiltration (24%) in the BD Nexiva™ Closed IV Catheter System group compared to the open system group.1,‡

The BD Nexiva™ Closed IV Catheter System needs fewer add-on devices, minimizing the number of manipulations which may lead to touch contamination and accidental disconnections.1,‡

Reduced costs

$1M
In a 2010 clinical study, the cost of using BD Nexiva™ IV Catheters with a customized securement dressing was 75% of the cost of a traditional catheter with a stabilization device and extension set.7

In a 2014 clinical study, results demonstrated a significant reduction in the rate of phlebitis (grade 2 or higher) (36%), catheter-related complications (25%), and infiltration (24%) in the BD Nexiva™ Closed IV Catheter System group compared to the open system group.1,‡

In a 2014 clinical study, using the BD Nexiva™ Closed IV Catheter System and replacing when clinically indicated led to a calculated cost reduction of approximately $1M/year/1,000 beds compared to an open system.4 #

The BD Nexiva™ Closed IV Catheter System needs fewer add-on devices, minimizing the number of manipulations which may lead to touch contamination and accidental disconnections.1,‡

The 2015 EPINet Report for Blood and Body Fluid Exposures reports the following statistics:

– The average blood and bodily fluid exposure rate was 11.4 per 100 average daily census with 49.4% of exposures to nurses
– 63.7% were wearing gloves
– 44.6% of exposures involved unprotected skin
– 79.9% of exposures involved the eyes, nose and mouth

In a 2015 EPINet Report for Blood and Body Fluid Exposures:

– The average blood and bodily fluid exposure rate was 11.4 per 100 average daily census with 49.4% of exposures to nurses
– 63.7% were wearing gloves
– 44.6% of exposures involved unprotected skin
– 79.9% of exposures involved the eyes, nose and mouth
References

* Compared to an open system.
† Compared to a non-blood control catheter.
‡ Compared to 96 hours with an open system.
§ Compared to B. Braun Introcan Safety® catheter with Bard Statlock IV Ultra® stabilization device.
~ Compared to a non-integrated IV catheter.

# Results and savings may vary for other institutions.


